
|Videos|April 10, 2020
Weekly Webinar Series Part 6: Managing Lung Cancer Patients Through the COVID-19 Pandemic
Advertisement
Episodes in this series

In part 6 of our weekly COVID-19 Webinar Series, Nathan Pennell, MD, PhD; Stephen Liu, MD; Charu Aggarwal, MD, MPH; H. Jack West, MD; and special guest speaker, Brendon Stiles, MD; share the latest updates and insights on the novel coronavirus.
The faculty shares outside perspectives on:
- Lung cancer surgery in the era of COVID-19
- Highlights from lung cancer data presented at the AACR Virtual Annual Meeting
- Directions and conclusions for the future of lung cancer care
Advertisement
Related to this article

Roswell Park Comprehensive Cancer Center broke ground on an expansion of the Roswell Park Broadview Community Outreach and Engagement Center.

A prespecified analysis showed benefit with anselamimab in patients with kappa light chain AL amyloidosis.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

The selective BCR::ABL1 inhibitor ELVN-001 produced major molecular responses in previously treated chronic-phase CML, including after asciminib progression.

Actinomycin D plus low-dose cytarabine and venetoclax produced high remission rates in a retrospective cohort of patients with NPM1-mutated AML.

Revumenib added to intensive chemotherapy produced deep, MRD-negative remissions with a manageable safety profile in newly diagnosed AML.

Ofirnoflast produced hematologic improvement in two-thirds of patients with ESA-refractory lower-risk MDS.
Advertisement
Advertisement
Trending on OncLive
1
Ofirnoflast Elicits Durable Transfusion Independence, Hematologic Improvement in Lower-Risk MDS
2
Revumenib Plus Chemo Yields High Response and MRD-Negativity Rates in Newly Diagnosed NPM1+ or KMT2A+ AML
3
ACTIVE Regimen Elicits High Response Rates in R/R NPM1-Mutated AML
4
Dr Gangat on Phase 2 Efficacy and Safety Data for DISC-3405 in Polycythemia Vera
5







